Daxor Corporation
Daxor Corporation
- Market cap
- $46.76M
- P/E ratio
- 6.45
Your view on DXR
Overview
What the company does, where it operates, and who runs it.
About Daxor Corporation
- Industry
- Medical - Instruments & Supplies
- Sector
- Healthcare
- CEO
- Michael Richard Feldschuh
- Headquarters
- 109 Meco Lane, Oak Ridge, TN, US
- Industry
- Medical - Instruments & Supplies
- Sector
- Healthcare
- CEO
- Michael Richard Feldschuh
- Headquarters
- 109 Meco Lane, Oak Ridge, TN, US
Daxor Corporation, a medical device company, provides blood volume measurement technology focused on blood volume testing.
The company develops and markets BVA-100 Blood Volume Analyzer, a diagnostic blood test to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms for used in a broad range of medical and surgical conditions.
The company was formerly known as Idant Corporation and changed its name to Daxor Corporation in May 1973. Daxor Corporation was incorporated in 1971 and is headquartered in Oak Ridge, Tennessee.
Stock Data
Price chart, volume, and trading data.
What moved it
FRC Fair Value Algorithm
What the FRC Fair Value algorithm says it is worth vs. the current price — FRC's own, on every stock.
About this section
Fair value for Daxor Corporation from FRC's valuation model, read against the market price. DXR last traded at $8.01, 6.4× trailing earnings — the estimate is read against that market price. The model runs on every stock on the platform and shows the estimate per share and the date it was calculated. A free account covers 3 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
About this section
Valuation, profitability, liquidity and leverage ratios for Daxor Corporation. Starting points for Daxor Corporation: P/E 6.4, EPS $1.25, beta 0.26 — an Medical - Instruments & Supplies name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
About this section
Reported vs. expected earnings history for Daxor Corporation. Trailing twelve-month EPS for Daxor Corporation stands at $1.25. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Wall Street Analyst Estimates
Analysts' price targets, ratings, and revenue and EPS estimates.
Buy
Targets, low to high
Analyst ratings
3 ratings- Strong Buy0
- Buy3
- Hold0
- Sell0
- Strong Sell0
Earnings per share estimates
| Per share | This quarterJun 2003 | Next quarterDec 2003 | This yearYear to Dec 2026 | Next yearYear to Dec 2027 |
|---|---|---|---|---|
| Average estimate | −$0.07 | −$0.04 | −$0.21 | −$0.03 |
| Lowest estimate | −$0.08 | −$0.05 | −$0.21 | −$0.03 |
| Highest estimate | −$0.06 | −$0.03 | −$0.21 | −$0.03 |
| Number of analysts | 16 | 7 | 1 | 1 |
| A year ago | — | — | $1.841 | — |
| Growth vs a year ago | — | — | — | — |
1The year-ago figure includes one-time items, so growth is not shown.
Revenue estimates
| Total | This quarterJun 2003 | Next quarterDec 2003 | This yearYear to Dec 2026 | Next yearYear to Dec 2027 |
|---|---|---|---|---|
| Average estimate | $900278.00 | $904183.00 | $9.30M | $16.40M |
| Lowest estimate | $720222.00 | $723346.00 | $9.30M | $16.40M |
| Highest estimate | $1.08M | $1.09M | $9.30M | $16.40M |
| Number of analysts | 16 | 7 | 1 | 1 |
| A year ago | — | — | $503424.00 | — |
| Growth vs a year ago | — | — | +1747.3% | — |
Financial Statements
Income statement, balance sheet, and cash flow statements.
About this section
Income statement, balance sheet and cash flow history for Daxor Corporation. Daxor Corporation has reported as a listed company since 1983. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
| Ticker | Type | Company | Sector | Industry | Mkt cap |
|---|---|---|---|---|---|
| ACETAdicet Bio, Inc. | Healthcare | Biotechnology | $23.4M | ||
| ADAGAdagene Inc. | Healthcare | Biotechnology | $68.5M | ||
| BEATHeartBeam, Inc. | Healthcare | Medical - Specialties | $21.6M | ||
| CRVOCervoMed Inc. | Healthcare | Biotechnology | $21.9M | ||
| GANXGain Therapeutics, Inc. | Healthcare | Biotechnology | $47.3M | ||
| GEGGreat Elm Group, Inc. | Financial Services | Asset Management | $67.6M | ||
| LITSLite Strategy, Inc. | Healthcare | Biotechnology | $24.1M | ||
| NEPHNephros, Inc. | Healthcare | Medical - Instruments & Supplies | $31.4M | ||
| Ticker | Type | Company | Sector | Exchange | Mkt cap |
|---|---|---|---|---|---|
| WHSIWearable Health Solutions, Inc. | Healthcare | OTC | $182,671 | ||
| WSTWest Pharmaceutical Services, Inc. | Healthcare | NYSE | $28.1B | ||
| XRAYDENTSPLY SIRONA Inc. | Healthcare | NASDAQ | $1.7B | ||
| YBGJYubo International Biotech Limited | Healthcare | OTC | $1.2M | ||
| ZJYLJin Medical International Ltd. | Healthcare | NASDAQ | $26.3M | ||
| SHWGYShandong Weigao Group Medical Polymer Company Limited | Healthcare | OTC | $3.0B | ||
| SMTISanara MedTech Inc. | Healthcare | NASDAQ | $300.6M | ||
| SOAGYSartorius AG | Healthcare | OTC | $82.3B | ||
| SOLVSolventum Corporation | Healthcare | NYSE | $14.7B | ||
| SRTOYSartorius Stedim Biotech S.A. | Healthcare | OTC | $209.8B | ||
| SSSGYSartorius AG | Healthcare | OTC | $15.8B | ||
| STAASTAAR Surgical Company | Healthcare | NASDAQ | $1.3B | ||
| Ticker | Fund | Fund assets | % of the fund |
|---|---|---|---|
| VTIVanguard Total Stock Market ETF | $689.2B in assets | 0.00% | |
| VUN.TOVanguard U.S. Total Market Index ETF | $20.1B in assets | 0.00% | |
| VEQT.TOVanguard All-Equity ETF Portfolio | $17.6B in assets | 0.00% | |
| VGRO.TOVanguard Growth ETF Portfolio | $10.9B in assets | 0.00% | |
| VBAL.TOVanguard Balanced ETF Portfolio | $6.0B in assets | 0.00% | |
| VUS.TOVanguard U.S. Total Market Index ETF (CAD-hedged) | $1.4B in assets | 0.00% | |
| VCNS.TOVanguard Conservative ETF Portfolio | $977M in assets | — | |
| VRIF.TOVanguard Retirement Income ETF Portfolio | $371M in assets | — | |
Largest holders first, then the funds most concentrated in DXR.
Institutional Ownership
Which funds and firms own the stock.
About this section
Which institutions hold Daxor Corporation, and how their positions are changing. At a $46.8M market value, institutional positions materially move Daxor Corporation's register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.
Insider Trading
Recent buying and selling by company executives.
About this section
Buying and selling by Daxor Corporation executives and directors. Shares of Daxor Corporation have traded between $6.55 and $14.00 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.
News
Latest headlines and market coverage.
About this section
Latest headlines and company announcements for Daxor Corporation. Coverage tracks Daxor Corporation within Medical - Instruments & Supplies (Healthcare). Press releases and market coverage, newest first.

Comments
Comments and replies from FRC members about this company.
No comments yet
Be the first to ask a question or say what you make of Daxor Corporation.